Research Scientist - CRISPR Gene Therapy - Gene Editing Institute
Req # JR54429
The Gene Editing Institute is the only research institute of its kind in the nation based within a community health care system. Led by gene editing pioneer, Eric Kmiec, Ph.D., and based in ChristianaCare's Helen F. Graham Cancer Center & Research Institute, the Gene Editing Institute is a worldwide leader in gene editing biomedical research in cancer and other inherited diseases, and the only one working in the same space with oncologists, genetic counselors and patients, bringing translational research from basic science to patient treatment to an entirely new level.
Christiana Care is currently seeking a Research Scientist - CRISPR Gene Therapy to work in the Gene Editing Institute. The Research Scientist will participate in all aspects of preclinical development work in new, targeted delivery system utilizing CRISPR gene therapy to treat NSCLC. The successful candidate will work on the design and optimization of CRISPR vectors in experimental lung cancer models. The candidate is also expected to develop proof-of-concept and preclinical studies for other solid cancers. The ideal candidate will have advanced expertise in CRISPR gene therapy and also in oncology, cell biology, molecular biology or biochemistry.
Other responsibilities to include:
- Be involved in the planning and execution of all aspects of preclinical development work for CRISPR gene therapy programs
- Lead laboratory research related to in silico, in vitro, and in vivo off-target analysis and characterizations for gene therapy products in preclinical research
- Perform CRISPR gRNA design, knockout / knock-in experimentation, and characterizations in in vitro and in vivo cell models
- Develop and implement proof-of-concept and preclinical research in solid tumor gene therapy
- PhD in cancer biology, molecular biology, cell biology, biochemistry, or a closely related field.
- Qualified candidate will have 0-4 years of relevant experience
- Three to seven years of industry experience preferred
- Candidates should also have authored at least one first author publication (either published or in the process of submission) in reputable journals; cancer research experience preferred.
- Must be proficient in CRISPR off-target analysis tools, CRISPR technology and its clinical application, cell-based models and in utilization of murine models, and performing cell biology, biochemistry, and molecular biology techniques.